Drug name: Trastuzumab

Related CSCTT Targets

ERBB2 [ref.1, 2, 3]P04626

Trastuzumab, Herceptin

Cas.no PubChem ID
Known Target
Receptor tyrosine-protein kinase erbB-22P04626
Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers. Trastuzumab is also being studied for the treatment of other cancers. It has been used with some success in women with uterine papillary serous carcinomas that overexpress HER2/neu.


  • [1] Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Magnifico, A., et al. (2009).Clin Cancer Res. 15(6):2010-21.
    19276287. [ 19276287 ]
  • [1] Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Chakrabarty, A., et al. (2013).Cancer Res.73(3):1190-200.
    23204226. [ 23204226 ]
  • [3] Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Diessner, J., et al. (2014).Cell Death Dis. 5:e1149.
    24675467. [ 24675467 ]

Back to top